Aaron Koenig
Chief Medical Officer Syndeio Biosciences
Seminars
Wednesday 16th September 2026
Panel Discussion: What Tools Can Be Used to Demonstrate Efficacy Through Early-Stage Clinical Trials? Evaluating Digital Biomarkers, EEG, PROs & Fluid Measures to Support with a Richer Analysis of Disease State
3:15 pm
- How multimodal digital biomarkers can sensitively capture early treatment signals and behavioral change before traditional clinical endpoints emerge
- The role of EEG and other neurophysiological readouts in demonstrating target engagement and pharmacodynamic effects during first in human and Phase 1/2 trials
- How structured patient reported outcomes enrich early datasets by capturing subjective symptom shifts that complement objective biomarker trends
- How fluid biomarkers – from inflammatory to neurodegenerative signatures – can provide quantifiable, mechanistic insight into early biological response and disease modulation
Wednesday 16th September 2026
Panel Discussion: Overcoming the Phase 2/3 Roadblock in Neuropsychiatric Drug Development: What Have We Learnt in 2026?
8:00 am
- How late stage failures continue to stem from heterogeneous patient populations and poor endpoint sensitivity, underscoring the critical need for biomarker driven stratification to boost Phase 2/3 success rates
- What 2025–2026 taught us about placebo inflation, highlighted by recent schizophrenia and depression trial outcomes, and how study site variability, digital tools, and speech/physiological biomarkers may mitigate expectation bias
- Why translational gaps persist across muscarinic, psychedelic, and neuroplasticity based mechanisms, and how emerging mechanistic and genomic biomarkers can better link target engagement with clinical effects in Phase 2/3
- How sponsors are redesigning global Phase 2/3 execution—leveraging faster moving regions, adaptive designs, and early signal-detection: to overcome long timelines, recruitment bottlenecks, and historically low CNS trial success rates
Wednesday 16th September 2026
Panel Discussion: Future Directions & Strategic Investment to Fuel the Next Wave of Neuropsychiatric Therapeutics
4:45 pm
- How emerging scientific modalities such as circuit level biomarkers, data integrated platforms, and next generation neuroplastogens are shaping the future landscape of neuropsychiatric innovation
- What investors and R&D leaders look for in early stage assets, including differentiated mechanisms, strong biomarker strategies, and clear pathways to clinical and commercial de risking
- How strategic capital allocation across discovery, translational technologies, and Phase 2/3 ready programs can build sustainable, multi mechanism therapeutic pipelines
- Where the field is heading next, and how cross disciplinary innovation and coordinated investment can accelerate the next transformative wave in neuropsychiatric therapeutics
Wednesday 16th September 2026
Chair’s Opening Remarks
7:55 am
Thursday 17th September 2026
Chair’s Opening Remarks
9:05 am
Wednesday 16th September 2026
Chair’s Closing Remarks
5:15 pm
Thursday 17th September 2026
Chair’s Closing Remarks
4:15 pm
